Sign in
4

Changes in Ownership

CYTOKINETICS INC Filed Acc 0001127602-24-008501

EVP Research & Development sold 32,604 shares at an average $67.56 ($2,202,606)

  • EVP Research & Development acquired 28,604 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Malik Fady Ibraham · EVP Research & Development

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-03-05 Sale : show line 1 in the form 10b5-1 −4,000 $67.53 $270,120 138,973 D
2024-03-05 Exercise or conversion : show line 2 in the form 10b5-1 +28,604 $6.67 $190,789 167,577 D
2024-03-05 Sale : show line 3 in the form 10b5-1 −28,604 $67.56 $1,932,486 138,973 D
Open-market sales · 32,604 sh · avg $67.56 · $2,202,606

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-03-05 Exercise or conversion : show line 4 in the form 10b5-1 Non-Qualified Stock Option (Right to Buy) −28,604 28,605 D
Loading xslF345X05/form4.xml…